Objective: While liver biopsy is the golden standard for liver-fibrosis diagnosis, it is also
invasive and has many limitations. Non-invasive techniques such as Magnetic Resonance Imaging
(MRI) need to be further developed for liver fibrosis staging. This study aimed to evaluate the
diagnostic accuracy of Gadolinium Ethoxybenzyl Diethylenetriamine Penta-acetic Acid (Gd-EOBDTPA)-
enhanced MRI for liver fibrosis through systematic review and meta-analysis.
Methods: This study comprehensively searched relevant article in PubMed, Embase, and the
Cochrane Library published from 2004 to 2018 to find studies analyzing the diagnostic accuracy of
Gd-EOB-DTPA-enhanced MRI for liver fibrosis. Two reviewers independently screened the retrieved
articles, extracted the required data from the included studies, and evaluated the methodological
quality of the studies. The pooled sensitivity, specificity, positive likelihood ratio, negative
likelihood ratio, diagnostic odds ratio, and Summary Receiver Operating Characteristics (SROC)
curve were assessed.
Results: This study finally included 16 studies (n = 1,599) and selected a random-effects model
based on the results of the I2 statistic to combine them. The areas under the SROC curve for the detection
of F1 or greater, F2 or greater, F3 or greater, or F4 liver fibrosis were 0.8669, 0.8399,
0.8481, and 0.8858, respectively.
Conclusion: Gd-EOB-DTPA-enhanced MRI showed a good diagnostic performance for staging liver
fibrosis, especially for F4 liver fibrosis.